Phase 2 Proof-of-Concept Study of the Safety and Efficacy of Alfimeprase to Rapidly Open Arteries and Restore Brain Function Following a Stroke

PHASE2TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

May 31, 2008

Study Completion Date

May 31, 2008

Conditions
Acute Ischemic Stroke
Interventions
DRUG

alfimeprase

Alfimeprase will be given as a single bolus of 1mg/2mL, or a split bolus of 5mg/2mL or 10mg/2mL in a three-tier dose escalation format. The 5mg and 10mg doses will be administered as split doses with 1/2 of the total dose given initially and 1/2 of the total dose given 30 minutes after the initial dose.

Trial Locations (22)

10032

Columbia Presbyterian Medical Center, New York

12208

Albany Medical Center Hospital, Albany

14203

Kalieda Health, MFH, Buffalo

15213

University of Pittsburg Medical Center, Pittsburgh

40202

Norton Hospital, Louisville

43214

Riverside Methodist Hospital, Columbus

45243

University of Cincinnati, Cincinnati

48912

Michigan State University, Sparrow Hospital, Lansing

50314

Ruan Neurology & Clinical Research Center, Des Moines

52242

University of Iowa Hospital, Iowa City

53215

St. Luke's Medical Center, Milwaukee

53342

University of Iowa Hospital, Iowa City

60611

Northwestern Medical Center, Chicago

67214

University of Kansas School of Medicine, Via Christi Regional Medical Center, Wichita

77030

Baylor College of Medicine, Houston

90024

UCLA Medical Center, Los Angeles

97239

Oregon Stroke Center, Portland

T2N 2T9

University of Calgary, Foothills Medical Centre, Calgary

V52 1M9

Vancouver General Hospital, Vancouver

L5B4A2

Trilium Health Center, Mississauga

M5T 258

University Health Network Toronto, Toronto

H3A 2B4

Montreal Neurological Institute, Montreal

Sponsors
All Listed Sponsors
lead

ARCA Biopharma, Inc.

INDUSTRY